ご寄付はこちら

論文

25. JACCRO CC-05/CC-06AR_B

UPDATE : 2018/10/05

Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer
Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zhang, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Yoshihiko Segawa, Hiroaki Tanioka, Yuji Negoro, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Masashi Fujii, Wataru Ichikawa
Molecular Cancer Therapeutics
 DOI: 10.1158/1535-7163.MCT-18-0694
 http://mct.aacrjournals.org/content/early/2018/09/29/1535-7163.MCT-18-0694

24. JACCRO CC-05/CC-06AR

UPDATE : 2018/08/27

Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer
 Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz
 Clinical Colorectal Cancer
 DOI: https://doi.org/10.1016/j.clcc.2018.08.002
 https://www.clinical-colorectal-cancer.com/article/S1533-0028(18)30353-0/abstract

23. JACCRO CC-11

UPDATE : 2018/04/17

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
 Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Misuzu Mori, Masahito Kotaka, Akinori Takagane, Masahiro Gotoh,
Masahiro Takeuchi, Masashi Fujii, Wararu Ichikawa, Takashi Sekikawa
 Oncotarget 2018; 9(27), 18811-20
 https://doi.org/10.18632/oncotarget.24702

22. JACCRO CC-14

UPDATE : 2018/08/27

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
 Hironaga Satake, Akihito Tsuji, Masato Nakamura, Masaaki Ogawa, Takeshi Kotake, Yukimasa Hatachi, Hisateru Yasui, Akinori Takagane, Yoshihiro Okita, Kumi Nakamura, Toshihide Onikubo, Masahiro Takeuchi, Masashi Fujii:
International Journal of Clinical Oncology 2018; 3(32), 490-6
 DOI: 10.1007/s10147-017-1228-5
 http://link.springer.com/article/10.1007/s10147-017-1228-5

21. JACCRO GC-06

UPDATE : 2017/04/24

Multicenter phase II study of trastuzumab plus S 1 alone in elderly patients with HER2 positive advanced gastric cancer (JACCRO GC-06)
Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, Kazuhiro Nishikawa, Chikara Kunisaki, Satoshi Matsusaka, Yoshihiko Segawa, Masato Nakamura, Kinro Sasaki, Narutoshi Nagao, Yukimasa Hatachi, Yasuhiko Yuasa, Shinya Asami, Masahiro Takeuchi, Hiroshi Furukawa, Toshifusa Nakajima on behalf of the JACCRO GC-06 Study Group
Gastric Cancer 2018; 21:421–27
 DOI: 10.1007/s10120-017-0766-x
 https://link.springer.com/article/10.1007%2Fs10120-017-0766-x

20. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/09/15

CEA response and depth of response (DpR) to predict clinical utcomes of first-line cetuximab treatment for metastatic colorectal cancer
Y. Sunakawa, A. Tsuji, T. Denda, Y. Segawa, Y. Negoro, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka, H. Tanioka, A. Takagane, S. Tani, T. Yamaguchi, T. Watanabe, M. Takeuchi, M. Fuji, W. Ichikawa
 Targeted Oncology 2017; 12(6), 787-94
 DOI: https://doi.org/10.1007/s11523-017-0527-0
 https://link.springer.com/article/10.1007/s11523-017-0527-0

19. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/05/19

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
Annals of Oncology 2017; 28 (8): 2030?31
Y. Sunakawa, A. Tsuji, M. Fujii, W. Ichikawa
 DOI: https://doi.org/10.1093/annonc/mdx231
 https://academic.oup.com/annonc/article-abstract/28/8/2030/3798690

18. JACCRO CC-05、JACCRO CC-06

UPDATE : 2016/10/12

Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials.
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
Clinical Colorectal Cancer 2017; 16(3): e171-180
 DOI: http://dx.doi.org/10.1016/j.clcc.2016.09.010
 http://www.clinical-colorectal-cancer.com/article/S1533-0028(16)30204-3/abstract

17. JACCRO CC-05/CC-06AR

UPDATE : 2016/10/12

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
A Sebio, S Stintzing, V Heinemann, Y Sunakawa, W Zhang, W Ichikawa, A Tsuji, T Takahashi, A Parek, D Yang, S Cao, Y Ning, S Stremitzer, S Matsusaka, S Okazaki, A Barzi, M D Berger and H-J Lenz.
The Pharmacogenomics Journal 2018; 18: 43–8
 DOI:10.1038/tpj.2016.69
 https://www.nature.com/articles/tpj201669

16. JACCRO CC-05

UPDATE : 2016/06/20

Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05)
A. Tsuji, Y. Sunakawa, W. Ichikawa, M. Nakamura, M. Kochi, T. Denda, T. Yamaguchi, K. Shimada, A. Takagane, S. Tani, M. Kotaka, H. Kuramochi, K. Furushima, J. Koike, Y. Yonemura, M. Takeuchi, M. Fujii, T. Nakajima.
Targeted Oncology 2016; 11(6): 799-806
 DOI: 10.1007/s11523-016-0445-6
 https://link.springer.com/article/10.1007/s11523-016-0445-6

15. JACCRO CC-05/CC-06AR

UPDATE : 2016/06/20

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Y. Sunakawa, D. Yang, M. Moran, S. H. Astrow, A. Tsuji, C. Stephens, W. Zhang, S. Cao, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka,Y. Segawa, T. Masuishi, M. Takeuchi, M. Fujii, T. Nakajima, W. Ichikawa, H. Lenz.
Cancer Biology & Therapy 2016: 17(7): 751-9
 DOI:10.1080/15384047.2016.1178426
 https://www.tandfonline.com/doi/full/10.1080/15384047.2016.1178426

14. JACCRO GC-04

UPDATE : 2016/04/21

Exploratory phase II trial in a multicenter setting to evaluate the clinical value of chemosensitivity test in patients with gastric cancer (JACCRO GC-04, Kubota memorial trial)
N. Tanigawa, H. Yamaue, S. Ohyama, S. Sakuramoto, T. Inada, Y. Kodera, Y. Kitagawa, K. Omura, M. Terashima, Y. Sakata, A. Nashimoto, T. Yamaguchi, K. Chin, E. Nomura, S.W. Lee, M. Takeuchi, M. Fujii, T. Nakajima
Gastric Cancer 2016; 19(2): 350-60
 DOI 10.1007/s10120-015-0506-z
 https://link.springer.com/article/10.1007/s10120-015-0506-z

13. JACCRO GY-01

UPDATE : 2016/02/09

Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
K. Umayahara, M. Takekuma, Y. Hirashima, S. Noda, T. Ohno, E. Miyagi, F. Hirahara, E. Hirata, E. Kondo, T. Tabata, Y. Nagai, Y. Aoki, M. Wakatsuki, M. Takeuchi, T. Toita, N. Takeshima, K. Takizawa
Gynecol Oncol 2016; 140 (2): 253-258
Doi: 10.1016/j.ygyno.2015.12.008

12. JACCRO CC-04

UPDATE : 2015/11/10

A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
S. Matsusaka, S. Ishihara, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shimbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima, T. Watanabe.
 Radiother Oncol. 2015 Aug;116(2):209-13.
 DOI: 10.1016/j.radonc.2015.08.002.
 http://www.thegreenjournal.com/article/S0167-8140(15)00421-1/abstract

11. JACCRO GC-05

UPDATE : 2015/11/10

Phase II/III study of second-line chemotherapy comparing irinotecan alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
K. Tanabe, M. Fujii, K. Nishikawa, C. Kunisaki, A. Tsuji, N. Matsuhashi, A. Takagane, T. Ohno, T. Kawase, M. Kochi, K. Yoshida, Y. Kakeji, W. Ichikawa, K. Chin, M. Terashima, M. Takeuchi and T. Nakajima on behalf of the JACCRO GC-05 study group.
Ann Oncol (2015) 26 (9): 1916-1922
 DOI: 10.1093/annonc/mdv265
 https://academic.oup.com/annonc/article/26/9/1916/189421

10. JACCRO CC-04

UPDATE : 2015/11/10

A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
S. Ishihara, S. Matsusaka, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shinbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima and T. Watanabe.
 Radiation Oncology (2015) 10:24
 DOI 10.1186/s13014-015-0333-8
 https://doi.org/10.1186/s13014-015-0333-8

9. JACCRO GC-03

UPDATE : 2015/11/10

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
W. Koizumi, Y. H. Kim, M. Fujii, H. K. Kim, H. Imamura, K. H. Lee, T. Hara, H. C. Chung, T. Satoh, J. Y. Cho, H. Hosaka, A. Tsuji, A. Takagane, M. Inokuchi, K. Tanabe, T. Okuno, M. Ogura, K. Yoshida, M. Takeuchi, T. Nakajima; JACCRO and KCSG Study Group.
J Cancer Res Clin Oncol 2014; 140: 319-28
 DOI: 10.1007/s00432-013-1563-5
 https://link.springer.com/article/10.1007/s00432-013-1563-5

8. JACCRO CC-03

UPDATE : 2013/12/01

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
M. Kochi, Y. Akiyama, T. Aoki, K. Hagiwara, T. Takahashi, K. Hironaka, F. Teranishi, F. Osuka, M. Takeuchi, M. Fujii, T. Nakajima.
Cancer Chemother Pharmacol 2013; 72, 1097-102
 DOI: 10.1007/s00280-013-2292-9
 https://link.springer.com/article/10.1007/s00280-013-2292-9

7. JACCRO PC-01

UPDATE : 2012/06/07

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
 Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.
 Cancer Chemother Pharmacol 2012; 69 : 1197-204.
 DOI: https://doi.org/10.1007/s00280-012-1822-1
 https://link.springer.com/article/10.1007/s00280-012-1822-1

6. JACCRO LC-01

UPDATE : 2011/09/01

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)
 Imamura, F. , Nishio, M. , Noro, R. , Tsuboi, M., Ikeda, N. Inoue, A. , Ohsaki, Y. , Kimura, Y. , Nishino, K., Uchida, J., Horai, T. 
 Chemotherapy 2011;57:357-62
 https://doi.org/10.1159/000330481

5. 統計学の基礎知識と解析ソフト

UPDATE : 2011/09/01

 統計学の基礎知識と解析ソフト
がん研有明病院 中島 聰總、防衛医科大学校 佐藤弘樹,
Drug Delivery System Vol.26 No2, 148-154(2011)

4. 日本がん臨床試験推進機構(JACCRO)の紹介

UPDATE : 2011/09/01

日本がん臨床試験推進機構(JACCRO)
中島 聰總、山口 俊晴、藤井 雅志、島田 安博、竹内 正弘
腫瘍内科 Vol.6 No.4, 305-311(2010)

3. JACCRO CC-02

UPDATE : 2011/09/01

Phase II study of FOLFOX4 with “wait and go” strategy as Wrst-line treatment for metastatic colorectal cancer
 Mitsugu Kochi, Wataru Ichikawa, Eiji Meguro, Hiroyuki Shibata, Takuji Fukui, Michitaka Nagase, Yutaka Hoshino, Masahiro Takeuchi,  Masashi Fujii, Toshifusa Nakajima.
 Cancer Chemother Pharmacol 2011;68:1215-1222
 https://link.springer.com/article/10.1007/s00280-011-1605-0

2. JACCRO GC-01

UPDATE : 2011/09/01

A phaseⅡ study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for serosa-positive gastric cancer (JACCRO GC-01 study);T.Yoshikawa, K.Omura, O.Kobayashi, A.Nashimoto, A.Takabayashi, T.Yamada, H.Yamaue, M.Fujii, T.Yamaguchi, T.Nakajima..  Europian J Surg Oncol 2010 ; 36 : 546-551 (2010)
 DOI: https://doi.org/10.1016/j.ejso.2010.04.011
 http://www.ejso.com/article/S0748-7983(10)00099-5/fulltext

1. FLADS systemの紹介

UPDATE : 2011/09/01

FLADS systemの紹介抗癌剤開発臨床試験へのJACCROの取り組み - FLADS(Flexible License Assisted Data Server)systemによるsupport -
中島聰總、山口俊晴、藤井雅志、島田安博、福井巌、曽根三郎、鶴尾隆、竹内正弘、小川一誠、青柳宏.
外科治療 Vol.97 No.5, 517-523(2007)